

Single Versus Repeated Intravenous Oncolytic Virus Infusions – Implications for Rationalised Scheduling of Therapy in Hepatocellular Carcinoma.

Authors: Karen J. Scott^{1†}, Emma West^{1†}, Rebecca Brownlie^{1†}, Fay Ismail¹, Christy Ralph², Matt Coffey³, Alan A. Melcher⁴, Alison Taylor¹, Salvatore Papa¹, Adel Samson^{1,2*}

Affiliations:

¹Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom.

²Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.

³Oncolytics Biotech Inc., Calgary, Alberta, Canada.

⁴The Institute of Cancer Research, London, United Kingdom.

†These authors contributed equally to this work.

*To whom correspondence should be addressed: Professor Adel Samson, a.samson@leeds.ac.uk, 0113 343 8449.

Running Title: Intravenous oncolytic virus therapy for HCC

Key words: Oncolytic viruses, intravenous therapy, hepatocellular carcinoma, liver damage, PD-L1

Word count: 5254

ABSTRACT

Background: Oncolytic virus (OV) immunotherapy stands to widely improve patient outcomes in multiple solid malignancies. However, to date, the scheduling of OV therapy, with single versus multiple infusions on consecutive days, has not been correlated with immunological or clinical response. In hepatocellular carcinoma (HCC) patients, where the background liver is frequently chronically injured, repeated dosing may have deleterious implications, resulting in off-target immune-mediated damage, thereby tipping the balance between favourable clinical response and hepatotoxicity. As such, elucidation of the optimum dosing regime is necessary to ensure therapy, whilst limiting damage to the background liver.

Methods: Herein, we expand upon our previous experience in neoadjuvant OV therapy to compare the immunological response from single versus repeated doses of reovirus in cancer patients. The impact of OV immunotherapy on HCC outcomes was examined *in vivo* following a high fat diet or induced liver fibrosis in the context of an abnormal background liver. Furthermore, we assess, in a syngeneic model of HCC, the potential immune-mediated toxicity of single versus multiple virus infusions in combination with PD-1 and PD-L1 blockade.

Results: Clinical trial data indicate that a single dose of reovirus is equivalent or superior to repeat doses in achieving: (a) induction of an inflammatory cytokine/chemokine response; (b) peripheral blood immune cell activation; and (c) migration of activated CD8+ CTLs. Repeated doses on consecutive days do not improve the amplitude or duration of the immune response following virus infusion. Furthermore, repeated viral dosing leads to an unwanted influx of activated T cells into background liver. An increase in PD-L1 expression on T cells resulting from a single virus dose was observed. Combination therapy of reovirus plus anti-PD-L1, but not anti-PD-1, limited tumour growth and extended survival *in vivo*.

Conclusions: A single dose of oncolytic virus is equivalent or superior to multiple consecutive doses in inducing an anti-tumour immune response. Combination immune checkpoint blockade with anti-PD-L1 holds potential to maximise the beneficial effects of a single dose, whilst simultaneously avoiding undesirable toxicities in the background liver in the context of HCC.

INTRODUCTION

Oncolytic viruses (OVs) are a promising immunotherapeutic approach in the treatment of many malignancies, with three agents having been approved for routine therapeutic use [1]. Their mechanism of action is dependent on OV infection and preferential replication in malignant cells with a subsequent ensuing anti-tumoural immune response. OVs exert effects on a patient's immune system in a multifaceted manner, resulting in many downstream responses. The release of inflammatory factors, including type I IFNs [2,3], followed by the subsequent induction of a proinflammatory cytokine/chemokine milieu, activates innate immune cell populations, both within the tumour and in the peripheral circulation. OV treatment is associated with the elevation of many chemokines necessary for the migration of immune cells, including cytotoxic CD8 T cells, critical mediators of anti-tumour immunity, into areas of inflammation, including the virus-infected tumour. The migration of lymphocytes from the peripheral blood in this way results in a transient peripheral blood lymphopaenia [4]. Furthermore, infection of tumour cells culminates in tumour cell death, causing release of tumour-associated antigens (TAAs) which are phagocytosed and presented by antigen presenting cells (APCs) to promote T cell anti-tumour priming [5]. Although OVs can be administered by intra-tumoural (*i.t.*) injection, the intravenous (*i.v.*) route is frequently preferred due to the convenience of administration and the likelihood of improved virus distribution to metastatic sites of disease. However, despite many finalised OV clinical trials, the optimum scheduling of *i.v.* infusions remains undefined. Trials completed thus far have incorporated both single [6,7] or multiple consecutive doses [8] within each two- to four-week treatment cycle, all with the primary aim of maximising OV delivery to the tumour in order to exert its anticancer effect. Furthermore, both individual [8] and numerous [9,10] cycles of treatment have been employed.

Whilst many believe that repeated doses within each cycle of treatment are required for therapeutic efficacy, proof of concept for a single shot cure was demonstrated in a patient who received a high dose of measles virus-NIS, where long term immune control was also observed after therapy [11]. However, evidence for tumour response following single *i.v.* administration is limited in the majority of patients, potentially due to the OVs being depleted by innate immune defences or due to neutralisation by pre-existing anti-viral antibodies [12]. Some evidence suggests that a dose fractionation strategy, i.e. repeated *i.v.* injections of divided doses within each two- to four-week cycle, can produce enhanced intra-tumoural penetration and distribution of OV [13,14]. Temporally spaced *i.v.* infusions may also allow the virus to better penetrate into distinct tumour microregions because the pattern of

microvascular tumour perfusion fluxes over time; notably, an increase in perfusion pressure can enhance the distribution of virus within the tumour and promote infection of tumour cells [14]. However, it is not clear whether repeated doses have improved therapeutic value and if they may conversely result in substantially greater side effects. Increased tissue distribution can theoretically lead to inflammation and lymphocytic infiltrates in off-target organs, raising the risk of autoimmune injury. Immune-mediated side effects are particularly important when considering patients with pre-existing chronic organ damage. Chronically damaged organs have less reserve capacity to cope with additional insults, including immune-mediated injury. Furthermore, long-standing organ damage is frequently associated with chronic inflammation, a process that results in the accumulation of abnormal antigens, which are more likely to be recognised as non-self, hence predisposing such organs to immune-mediated injury following OV infusion. Perhaps the best example of this scenario is to be found in patients with hepatocellular carcinoma (HCC), where the majority have underlying liver cirrhosis and reduced hepatic reserves, as a result of chronic liver inflammation, damage and repair. Multiple OVs have been tested in HCC [15], with mixed results thus far. A key component to the success of OV therapy in HCC is the balance between anti-HCC immunity and off-target immune-mediated damage to the cirrhotic background liver; notably, a specific case reported that *i.v.* administration of a non-replicating adenovirus proved fatal [16]. Rationalised scheduling of *i.v.* infusions is therefore paramount, in order to maximise benefit and minimise harm.

Herein, we build on our experience of neoadjuvant *i.v.* reovirus clinical trials, to compare the peripheral blood immune response in patients receiving either a single dose or repeated daily infusions of reovirus for up to five days, within a single cycle of therapy [7,8]. Reovirus is a naturally occurring double stranded RNA OV, which usually results in asymptomatic infection [17]. Oncolytic reovirus has been extensively used in early phase clinical trials and shown to have a broad range of activity against many malignancies, with studies now in development for its use in the context of HCC. We previously published data from our clinical trials showing successful delivery of virus to tumours following both a single and repeated doses of reovirus. Here, we report that irrespective of the dosing strategy, both studies show evidence of a peripheral blood immune response and lymphopaenia, indicative of potential lymphocyte migration to sites of tissue inflammation. The amplitude of this response in patients who had received a single reovirus infusion was overall equal to, or greater than, the amplitude of response in patients who had received repeated infusions. Furthermore, using pre-clinical animal models of HCC, we demonstrate that multiple *i.v.* reovirus infusions result in elevated immune infiltrates in the background liver, in comparison to a single infusion. This

proinflammatory response in a physiologically-compromised background liver is associated with indications of further liver damage, evident by increased liver enzyme activity. We go on to examine the possibility of combining OV therapy with immune checkpoint blockade, with the potential to avoid multiple doses and their subsequent deleterious effects. Upregulation of PD-1 and PD-L1 expression on T cells induced by virus exposure was exploited as a combination approach with OV; reovirus plus anti-PD-1 had no benefit to overall efficacy. However, reovirus plus anti-PD-L1 resulted in reduced tumour growth and increased overall survival in a syngeneic *in vivo* HCC model. Moreover, a single dose of reovirus within this combination therapy was equally effective to multiple doses.

MATERIALS AND METHODS

Reovirus

Clinical-grade Dearing Type III Reolysin[®] was kindly provided by Oncolytics Biotech Inc., Calgary, Canada. For *in vitro* and *in vivo* studies, reovirus stocks of 2×10^9 plaque-forming units (pfu)/ml was stored at -80 °C until needed.

Clinical trial protocols

Protocols, patient information sheets and consent forms for both trials were approved by the United Kingdom Medicines and Healthcare products Regulatory Authority (MHRA), as well as regional ethics review and biological safety committees at St. James's University Hospital, Leeds, UK. Written, informed consent was obtained from all patients in accordance with local institutional ethics review and approval. Both trials were open-label, non-randomised, single centre studies carried out at St. James's University Hospital.

Reo013 (EUDRACT number 2007-000258-29):

Recruited 10 patients with colorectal cancer metastatic to the liver who were scheduled to undergo planned resection with radical intent. Study recruitment commenced in January 2009 and trial concluded in July 2011. Eligibility/exclusion criteria as previously described [8]. Study patients received 1×10^{10} TCID₅₀ Reolysin[®], administered daily by *i.v.* infusion over 60 mins, for a maximum of five consecutive days. Data from this trial is termed as coming from 'repeated doses' of virus.

Reo013 Brain (EUDRACT number 2011-005635-10):

Recruited nine patients prior to their planned de-bulking neurosurgery; six with recurrent high-grade glioma and three with metastatic tumours to the brain (one primary colorectal cancer and two primary melanoma). Study recruitment commenced in July 2013 and

concluded in November 2014. Eligibility/exclusion criteria as described [7]. Patients received a single infusion of 1×10^{10} TCID₅₀ Reolysin®, administered by *i.v.* infusion over 60 mins. Data from this trial is termed as coming from ‘one dose’ of virus.

Collection of peripheral blood samples from trial patients

Peripheral blood was collected into K₃EDTA vacuette tubes (Greiner) and processed, where possible, within one hour of venepuncture. Blood samples were taken pre-virus infusion (‘pre’ or ‘baseline’), day 3 (‘d3’), pre-surgery (‘S’) and one month post-surgery (‘1M’).

Patient lymphocyte counts

Full blood counts were performed where appropriate as part of standard clinical care. The Patient Pathway Manager and Results Server systems were used to acquire total lymphocyte counts throughout treatment.

Isolation of plasma from patient peripheral blood

Peripheral blood was centrifuged for 10 mins at 2000 g and plasma harvested from the resulting upper layer (above red blood cells). Aliquots were stored at –80 °C until required for cytokine/chemokine analysis.

Whole blood immunophenotyping of patient samples

Whole blood was added to pre-aliquoted antibodies (see below) and left for 30 mins at 4 °C protected from light. 1X FACS-lysing Solution (BD Biosciences) was added and tubes were immediately vortexed before being incubated for 10 mins at room temperature protected from light. A 300 g spin for five mins at 4 °C was performed, supernatants discarded and FACS buffer (phosphate-buffered saline (PBS) containing 1 % (v/v) foetal calf serum (FCS; Biosera) and 0.1 % (w/v) sodium azide (Sigma)) added before a second spin as above. Cells were fixed in 1 % (w/v) paraformaldehyde (PFA; Sigma) and stored at 4 °C until flow cytometry was performed. Cells were acquired using a FACS Caliber flow cytometer and analysed using Cell Quest software or an LSR II 3 Laser Cytometer and FACS Diva software (both BD Biosciences). Appropriate isotype controls were used for all immunophenotyping. All post-treatment samples are expressed as relative fold-change compared to pre-treatment samples.

Reo013 (repeated doses) antibodies:

Anti-human: CD3-APC, CD4-PerCP, CD8-PerCP, CD14-PerCP, CD19-APC, CD69-FITC (all BD Biosciences).

ReoBrain (single dose) antibodies:

Anti-human: CD3-PECy7, CD4-V500, CD8-BV500, CD14-BV510, CD19-BV421, CD56-FITC (all BD Biosciences) and CD69-APC (Miltenyi).

Chemokine and cytokine multi-plex analysis

Bio-Plex Pro™ Cytokine and Chemokine Assays (21-plex, human group I and 27-plex, human group II; BioRad) were used to determine levels of soluble mediators in plasma samples throughout treatment, as per manufacturer's instructions. Data is expressed as relative fold change in post-treatment samples compared to pre-treatment samples.

Subcutaneous HCC model

Female BALB/c aged 8-10 weeks were purchased from Charles River Laboratories, UK. To induce tumours, 1MEA HCC cells (between 1×10^6 and 1×10^7) were injected subcutaneously (*s.c.*) into the flank and tumour growth was quantified by calliper measurement. Once tumours had established (approximately day 21), one or three doses of reovirus or PBS was administered on consecutive days (days 1-3; 1×10^7 pfu/dose) either *i.v.* or *i.t.* (as indicated). In some experiments, either 100 µg In Vivo plus anti-mouse PD-L1 (B7-H1) or In Vivo Plus IgG2b isotype control (BioXcell) or 100 µg anti-mouse PD-1 or IgG1 anti-mouse β-Gal isotype control (InvivoFit™, InvivoGen) (as indicated) was administered intraperitoneally (*i.p.*) for three days after reovirus treatment (days 4, 5 and 8). This cycle of treatment was repeated at day 15. Animal procedures involving subcutaneous HCC tumours were performed under the approved UK Home Office project license PP1816772 (held by AS) in line with the Animal (Scientific Procedures) Act 1986.

Immune infiltration into tumour and liver

The *s.c.* HCC *in vivo* model was initially used to replicate the patient blood sampling schedule. Here, tumours and livers were harvested 72 hours after last virus infusion and stored in formalin for IHC analysis. Formalin-fixed paraffin-embedded (FFPE) tissue sections were stained with rabbit anti-mouse CD4 or CD8 antibody (both Abcam; both 1:500) and ImmPRESS-HRP anti-rabbit IgG (peroxidase) secondary antibody (Vector). Positive staining was visualised using ImmPACT DAB Peroxidase (HRP) Substrate kit (Vector). Control sections contained no primary antibody. Digital images were acquired at x20 magnification and quantified using Aperio ImageScope software v12.3.3.5048 (Leica Biosystems).

To further investigate the nature and duration of immunological response to reovirus treatment, tumours, livers and tumour-draining lymph nodes (dLN) were harvested at day 3 or day 9 after the last virus dose and analysed by flow cytometry. A single-cell suspension was

prepared via disaggregation of tissue through a 70 µm cell sieve (Corning) and washes in PBS. Immunophenotyping was performed using anti-mouse CD3-FITC (Miltenyi), CD8-BUV395 (BD Biosciences), CD4-APC-cy7 PD-L1-PE/Dazzle, PD1-BV605, CD69-BV650 (all Biolegend) and analysed by flow cytometry. Data was acquired on a Cytoflex LX cytometer (Beckman Coulter) and analysed using FlowJo™ software (BD Biosciences).

Liver fibrosis *in vivo* models

Male C57BL/6 mice aged 12 weeks were purchased from Charles River. Mice (n=5/group) were maintained on a high fat diet (HFD) (Fat Calories 60 %, 1/2" Soft Pellets; Bio Serv) for 13 weeks or injected *i.p.* with 0.5 ml/kg body weight of carbon tetrachlorine (CCl₄; Sigma) diluted in mineral oil twice a week for 4 weeks, followed by once a week for a further 8 weeks. Aged matched control mice were kept on a normal diet. Groups of mice were then injected *i.v.* with either PBS, one or three doses of 1x10⁷ pfu reovirus on consecutive days. On day 4, livers were harvested for analysis by flow cytometry, as previously described. Blood serum (100 µl) was analysed using the 24 Comprehensive Test Plus disc on the SMT-120V fully automated veterinary Biochemistry analyser (Seamaty). Animal procedures involving liver fibrosis were performed under the approved UK Home Office project license PP0972946 (held by SP) in line with the Animal (Scientific Procedures) Act 1986.

Statistical analysis

GraphPad Prism was used to perform paired T tests on clinical trial data to define statistical significance in response to therapy, where indicated. *In vivo* data was analysed using unpaired T tests and long rank (Mantel-Cox) test. *P<0.05, **P<0.01, ***P<0.001 ****P<0.001.

RESULTS

Reovirus-induced inflammatory cytokine response

To assess the early peripheral blood immune response to either a single or multiple *i.v.* infusions of reovirus, we analysed patient blood samples obtained from two separate clinical trials conducted at a single centre. In the first trial [8], patients received up to five consecutive daily infusions of reovirus ('repeated doses'), with each infusion containing 1x10¹⁰ TCID₅₀ and in the second trial [7], patients received reovirus in a single dose ('one dose'), also at 1x10¹⁰ TCID₅₀. Clinical data, alongside evidence of virus within tumour tissue, were previously reported [7,8]; herein we expand on our published observations and show the peripheral immune response to reovirus infusion is achieved by a single dose of virus. Peripheral blood samples were collected as per original trial sampling schedules depicted in Figure 1A, at

baseline (pre) and at indicated time points throughout treatment. Plasma samples were analysed for the presence of both cytokines that stimulate cellular anti-cancer immunity (Figure 1B) and those that negatively regulate cellular immunity (Figure 1C). The results show that regardless of whether a patient is given a single or repeated doses of reovirus, a consistent pattern of cytokine response is observed. In both trials, significantly increased secretion of type I interferon (IFN)- α was observed, as would be anticipated following viral infection [2,3]. Furthermore, many other IFN-stimulated inflammatory cytokines, for example, IL-2Ra, IL-16 and IL-18, were also elevated by day 3 after virus infusion regardless of whether patients had received either a single or repeat infusions of reovirus. These cytokines are predominantly involved in stimulating T cells [18,19] and NK cells [20] during an inflammatory response, critical immune cells in the anti-cancer response following OV therapy. Conversely, Th2 cytokines known to be involved in the suppression of cellular anti-cancer immunity, IL-4 and IL-5 [21], were observed to decrease following reovirus treatment in both groups of patients, amounting to a significant reduction in concentrations following a single but not repeated infusion. The peak in proinflammatory cytokines and the recovery of IL-4 and IL-5 returns to pre-treatment levels by the time of surgery regardless of the number of infusions received. Overall, this indicates that both single and repeated doses of virus have similar effects in the induction of a pro-inflammatory (Th1) systemic immune environment, in conjunction with a dampening of the anti-cellular immunity (Th2) cytokine response, suggesting that multiple doses are not necessary in the initial stages of immune anti-tumour activation, following OV infusion.

Reovirus-induced immune cell activation

As may be predicted by the induction of a pro-inflammatory cytokine response, both repeated and single doses of reovirus caused similar activation of CD4+ and CD8+ T-cells, demonstrated by an upregulation in expression of CD69, an early activation marker (Figure 1D). CD69, which is known to be upregulated in response to many cytokines including type I IFNs and IL-18 [22–24], increased significantly by day 3, before returning to pre-treatment levels by surgery following both repeated and single doses of reovirus. A similar occurrence was observed on CD19+ B cells and CD14+ monocytes, in response to a single infusion, although not in response to repeat infusions (Figure 1E). Furthermore, in patients receiving a single dose of reovirus, an elevation in CD69 expression on both NK (specifically cytotoxic CD56^{dim} cells) and NKT cells was also apparent (Figure 1F). Whilst NK and NKT cell CD69 expression wasn't assessed on patients receiving repeat reovirus infusions, these data again demonstrate that a single dose, within any given cycle of reovirus treatment, is sufficient for the activation of multiple immune sub-sets, with the peak of activation occurring at day 3.

Reovirus-induced fluctuations in peripheral T cells

Analysis of patients' full blood counts during reovirus therapy revealed a transient lymphopenia at day 3, similar in magnitude following both single and repeated infusions, which returned to baseline levels in subsequent weeks (Figure 2A). Peripheral blood lymphopenia is commonly observed following both pathogenic and therapeutic virus infection and has been associated with the trafficking of immune cells to both sites of tissue inflammation and lymph nodes, where an adaptive response can be initiated [4]. Flow cytometric analysis of specific immune cell subtypes revealed that many lymphocytes decreased proportionally in the peripheral blood, contributing to this lymphopenia; CD4+ T cells are at a significantly reduced frequency following both single and repeat doses of reovirus, whilst CD8+ T cells were significantly reduced following a single, but not repeated doses (Figure 2B). Analogous to this, CD19+ B cells are also present at lower levels on day 3, although this was again more marked following a single rather than repeated doses (Figure 2C). In contrast, the proportion of CD14+ monocytes appears elevated in peripheral blood after viral therapy at day 3, rising proportionally to other lymphocyte subsets (Figure 2C). In keeping with the observed lymphopenia, changes in the concentrations of many chemokines that are associated with the trafficking of immune cells were apparent when patient plasma was examined. Specifically, interferon gamma-induced protein 10 (IP-10), monokine induced by gamma interferon (MIG) and macrophage inflammatory protein 1- β (MIP-1 β) levels peaked at day 3 following virus infusion, before falling back to baseline at subsequent time points (Figure 2D). All three chemokines are primarily implicated in immune cell chemotaxis and tissue infiltration of CD8+ T cells [25], CD4 T cells [26], NK cells [27] and monocytes [28], a necessary process in OV-induced anti-tumour immunity. Again, the increase in these chemokines was either comparable for single versus repeated infusions, or even higher with a single infusion. This indicates that a single OV infusion is sufficient or potentially superior to multiple infusions in creating an immune environment in the blood, which may be permissive to lymphocyte migration into the tumour.

Reovirus-induced T cell infiltration in HCC

The need to balance clinical efficacy and toxicity with intravenous OV therapy is perhaps best illustrated in patients with HCC, where the background liver is highly susceptible to immune-mediated damage. To determine the potential effectiveness of single versus repeat reovirus doses in HCC, we utilised a syngeneic immunocompetent model in Balb/c mice. Mice were administered with either one or repeated doses of *i.v.* reovirus to determine the pre-clinical

effect on T cell infiltration into tumour and liver. Figure 2E depicts the influx of CD4+ and CD8+ T cells into the tumour and liver at day 3 following one dose or the last of repeated doses of reovirus. Interestingly, the level of CD4 cells within the tumour are not increased by reovirus; in fact, one dose causes a reduction in CD4 T cells within the liver. In contrast, there is a significant increase in CD8+ staining within the tumour and an even greater CD8+ T cell infiltration into the liver, which, in the context of a damaged liver, may result in erroneous immune-mediated deleterious effects.

Potential off-target effects of OV therapy on chronically damaged HCC livers

As previous data indicates a considerably greater influx of CD8+ T cells into the liver following reovirus treatment, we examined the toxicity of OV therapy on chronically damaged livers in order to model the scenario in HCC patients with impaired background liver function. Liver damage was induced in mice before administering either single or multiple doses of reovirus, followed by assessment of liver damage and immune cell infiltration. One cohort was maintained on a high fat diet (HFD) for 13 weeks, gaining on average over 90 % of starting weight (Supplementary Figure S1), while another cohort was injected with CCl₄ to induce hepatic fibrosis. After reovirus delivery, liver T cells were assessed by flow cytometry for CD69 and PD-L1 expression whilst biochemistry analysis was performed on serum to measure liver enzyme activity including aspartate aminotransferase (AST), alanine transaminase (ALT), albumin (ALB), total bile acids (TBA), alkaline phosphatase (ALP) and creatine kinase (CK) (Figure 3). Within the cohorts, administration of either a single or multiple doses of reovirus resulted in a similar increase in expression of CD69 and PD-L1 on hepatic-resident CD4 and CD8 T cells, showing no further T cell activation advantage of multiple doses (Figure 3A). With regard to liver function (Figure 3B), AST, ALT, ALB and ALP from control mice injected with PBS all fell within the normal range of detection (indicated by the grey band). Reovirus did not significantly alter this, with the exception of ALB, which was comparably reduced by both single and multiple doses of reovirus, a pattern seen across all cohorts of mice; this is indicative of reduced liver function. Similarly, CCl₄ injections alone had marginal effect on enzyme levels; however, the administration of reovirus to these mice resulted in elevations of AST and ALT to above that of the healthy range, again suggesting reduced liver function. No significant differences in levels of any solutes between single or multiple doses were observed in CCl₄-pretreated mice. Mice fed the HFD and treated with PBS had high levels of AST and ALT compared to control mice. A single dose of reovirus had no effect over and above PBS for both AST and ALT in HFD-mice, yet AST was significantly increased (two-fold over a single reovirus dose and over five times the healthy range) upon multiple reovirus injections, suggesting a greater degree of liver damage. The variable, albeit largely unchanged, levels of

CK suggest that this AST increase was a result of liver and not myocyte damage. Furthermore, multiple doses of reovirus also increased TBA in CCl₄ and HFD mice and, in some cases, ALP in HFD mice. Overall, hepatic T cell activation by single and multiple doses of reovirus is comparable; however in the context of a damaged liver, multiple doses are more harmful than a single dose, as indicated by a change in solutes which are associated with a pronounced reduction in liver function.

Clinical efficacy of reovirus can be enhanced by combination with PD-L1

Previous studies have shown no clinical benefit of reovirus monotherapy (reviewed in [29]). It is now recognised, however, that OV monotherapy induces expression of the immune checkpoint receptor, PD-1 and its ligand PD-L1, which act to limit immune-mediated injury but also inhibit the efficacy of OVs [7,30,31]. A multi-modal combination approach is therefore necessary to optimise OV effectiveness. Multiple early-phase clinical trials employing the combination of an OV with PD-1 or PD-L1 blockade have shown good evidence for synergistic efficacy [7,30,32–34]. More recently, PD-L1 inhibition has become standard of care in advanced HCC [35].

Given our previous data showing that a single dose of reovirus was sufficient to activate T cells (Figures 1, 2 and 3A), we sought to determine the expression profiles of reovirus-induced PD-1 and PD-L1 on T cells in tumour-bearing mice after a single dose. Figure 4 shows that PD-L1 was significantly upregulated on a large proportion of CD4 and CD8 T cells in dLN (>90 %), liver (>80 %) and tumour (>60 %) 3 days after *i.v.* reovirus, with levels reducing by day 9. Conversely, reovirus did not upregulate PD-1 expression on CD8 T cells and only a small proportion (<5 %) of dLN and liver CD4 T cells by day 9 (Figure 4A and B). CD69 was also observed to increase following a single reovirus injection by day 3, most notably on dLN T cells.

We sought to define whether *i.t.* injection would enable more focused tumour immune activation, whilst protecting the background liver. Although *i.t.* injection appeared to upregulate CD69 expression to a greater level than the *i.v.* route, predominantly in tumour compared to liver, no significant differences in PD-1 and PD-L1 upregulation were observed between *i.v.* and *i.t.* administration (Supplementary Figure S2). This indicates that *i.t.* delivery of reovirus is unlikely to be less hepatotoxic than *i.v.* delivery.

We next determined the potential for combination reovirus-PD-1/PD-L1 blockade in HCC, in the context of multiple versus single reovirus injections (Figure 5). As expected, both single and multiple doses of reovirus alone had no impact on tumour burden or survival. Combining single or multiple injections of reovirus with anti-PD-1 also did not significantly change tumour

growth or survival (Figure 5A & B). However, the addition of anti-PD-L1 in combination with reovirus did significantly delay tumour growth and prolong survival (Figure 5C & D). Importantly, multiple doses of reovirus did not enhance the efficacy of this combination therapy over that observed from a single dose. These data suggest that an effective combination reovirus-anti-PD-L1 approach would only require a single dose of virus within each cycle of therapy, which is likely to be particularly important in patients with underlying liver cirrhosis, in order to avoid further immune-mediated damage.

DISCUSSION

Despite a plethora of both pre-clinical and clinical trials over recent years investigating the potential of OV_s in the immunotherapeutic treatment of many cancer types, the optimum scheduling and dosing regime has not yet been elucidated. A single 'one-shot' dose avoids the subsequent neutralisation by virus-specific antibodies, although a multiple-dose approach may, in theory, be more clinically effective due to sustained exposure to virus. To date, the scheduling of OV therapy, with single versus multiple infusions on consecutive days, has not been correlated with immunological or clinical response in any solid malignancies. HCC tumours have a considerably more problematic physiology; chronic injury to the liver due to lifestyle factors or HBV/HCV infection induces long-term damage, which is highly susceptible to off-target immune-mediated harm. In these patients, repetitive dosing may have undesirable effects to the damaged liver, resulting in hepatotoxicity, which may outweigh the clinical advantages of therapy.

Here we present data in an amalgamated study from two separate clinical trials using reovirus in different dosing regimens that indicates a single dose is adequate to achieve immune activation. Although delivery of OV to the tumour might be anticipated with repeated doses, particularly following the onset of immune exhaustion after the first dose, we have previously shown that a single dose is able to penetrate and infect tumour tissue [7]. Furthermore, as OV_s replicate in malignant cells, the delivery of a lower dose to tumour may be sufficient for subsequent viral amplification, bypassing the need for repeated doses. A single dose may, therefore, be sufficient to generate a subsequent tumour-specific pro-inflammatory environment, equivalent to that generated by multiple doses. Our results indicate that a single infusion of oncolytic reovirus induces a comparable and possibly improved inflammatory cytokine and chemokine response in comparison to repeated consecutive infusions of virus in patients. A single infusion was also associated with equivalent, if not greater, immune cell activation and migration of immune cells away from the vascular compartment, likely to sites of virus infection in tumour. The fact that multiple virus infusions

had no additional benefit over a single dose likely represents immune cell refractoriness following the initial stimulation by the first dose, a previously observed phenomenon [36]. Likewise, repeated dosing regimens have been associated with diminishing results with each successive OV treatment [37]. In fact, there are no preclinical or clinical studies which clearly demonstrate the superiority of repeat administrations over a single dose within each cycle of treatment [37].

Utilising complementary *in vivo* studies, we show, in parallel to the evidence that a single dose is immunologically equivalent to multiple doses in patients, that unfavourable responses are associated with repeated infusions; a greater influx of proinflammatory T cells into the liver following multiple OV doses, which, in the context of HCC, may have damaging off-target effects.

Almost all HCC patients have underlying liver fibrosis or cirrhosis [38]; the most common aetiologies being non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, autoimmune hepatitis, metabolic syndrome, viral hepatitis and alcohol consumption [39], all of which are strong risk factors for HCC. To assess the impact of liver health on the ability to tolerate reovirus, we used two models of chronic liver damage; HFD and multiple injections of CCl₄ to induce liver fibrosis. In both settings and in keeping with our clinical trial data, the activation of T cells by a single dose was comparable to multiple doses of reovirus. However, in general, mice subjected to liver damage, particularly HFD, had abnormal amounts of liver enzymes, which were further exacerbated by reovirus administration. Most strikingly, AST was increased up to five times the healthy range when reovirus was given in multiple doses to HFD mice in comparison to a single dose or PBS. Patients with greater than five times the upper limit of normal AST are considered to have moderate hepatocellular injury [40]. Taken together, these studies highlight the need to carefully balance the potential damaging effects of multiple doses of OV with beneficial clinical outcome in the context of HCC.

A multi-modal combination approach, commonly involving checkpoint blockade, may be necessary for optimum OV efficiency. Indeed, PD-L1 inhibition is standard of care in advanced HCC [35]. Our HCC *in vivo* model demonstrates a highly significant transient elevation in PD-L1 expression on both CD4⁺ and CD8⁺ T cells from tumours, livers and dLNs in response to a single reovirus injection, peaking at day 3 then reducing at later time points. This transient upregulation was utilised in a combinatorial approach in an *in vivo* model of HCC. Here, we show reovirus alone has no impact on tumour burden, yet when combined with anti-PD-L1 antibodies, reovirus could significantly delay tumour growth and prolong survival, with a single dose being as effective as multiple doses. The same phenomenon was not observed when using anti-PD-1/reovirus combination. These data suggest that an effective

combination reovirus-PD-L1 approach would only require a single dose of virus within each cycle of therapy, thereby limiting potential further damage to an already compromised background liver.

In HCC, strategies for combination immunotherapies, such as OV with immune checkpoint blockade (ICB), are currently being tested in clinical trials (NCT04665362). In the context of HCC, however, the background liver tissue is usually abnormal or cirrhotic and particularly susceptible to immune-mediated injury. This is exemplified by the higher rates of hepatic injury following ICB in patients with HCC, in comparison to other cancer types [41–43]. Studies have shown that ICB is associated with the infiltration of large numbers of CD8+ T cells into background liver tissue [44]. Hence, the combination of OV and ICB therapy should be scheduled to limit the infiltration of immune cells into background liver tissue, to reduce the incidence and severity of immune-mediated hepatitis, particularly in the treatment of HCC. Our data collectively suggest that a combinatorial approach comprising a single OV infusion within each cycle of therapy is likely to be safest for the background liver and equally effective in inducing anti-tumour immunity.




Figure 1: Effects of a single or repeated infusions of *i.v.* reovirus on patient peripheral immunological responses

(A) Trial schema for ‘repeated doses’ study and ‘one dose’ study, showing timing of reovirus infusions and peripheral blood sample collection. Multi-plex analysis was performed on

patient plasma samples taken throughout study periods to determine secretion of **(B)** immune-stimulatory and **(C)** immune-inhibitory cytokines. (Data is presented as fold-change from baseline (pre-infusion) sample; each line denotes an individual patient; repeated dose study n=6, single dose study n=9.) Whole blood immunophenotyping of patient samples was performed throughout study periods and cell-surface CD69 expression was determined on: **(D)** CD4⁺ T cells and CD8⁺ T cells, **(E)** CD19⁺ B cells and CD14⁺ monocytes and **(F)** CD3⁻ CD56⁺ NK cells, CD3⁺ CD56⁺ NKT cells, as well as CD56^{bright} and CD56^{dim} NK cells (of those patients given a single dose of reovirus only). (Data is presented as mean ± SEM fold change from baseline (pre-infusion) sample; repeated dose study: n=4; single dose study: n=9. Paired T tests; *P<0.05, **P<0.01, ***P<0.001).




Figure 2: Effect of single or repeated infusions of *i.v.* reovirus on relative abundance of T cells in peripheral blood and tissue.

(A) Changes in patient total lymphocyte count over the treatment period. (Data is presented as fold-change from baseline (pre-infusion) with each line representing an individual patient.) Whole blood immunophenotyping of patient samples was performed to determine

changes in: **(B)** CD4⁺ T cells, CD8⁺ T cells and **(C)** CD19⁺ B cells and CD14⁺ monocytes. (Data is presented as mean ± SEM fold-change from baseline (pre-infusion) sample; repeated dose study n=10, single dose study n=9.) **(D)** Multi-plex analysis was performed on patient plasma samples taken throughout study periods and change in secretion of the chemokines IP-10, MIG and MIP-1β was determined. (Data is presented as fold change from baseline (pre-infusion) sample; each line represents an individual patient; Repeated dose study n=6, single dose study n=9; Paired T tests; *P<0.05, **P<0.01, ***P<0.001.) **(E)** 1MEA tumour-bearing mice were treated with PBS control (white bars) or by a single (light grey bars) or repeated (dark grey bars) *i.v.* doses of reovirus. Livers and tumours were harvested 72 hours after the final virus dose. IHC was performed on FFPE tissue for CD4⁺ and CD8⁺ T cells and quantified as immune cell positivity per mm² of tissue. (Data is presented as mean ± SEM for n=5 per group; unpaired T tests; *P<0.05, **P<0.01).




Figure 3: Effect of single or repeated infusions of *i.v.* reovirus on a physiologically-damaged background liver.

PBS (white bars), a single dose (grey bars) or repeated doses (black bars) of reovirus were administered to mice with induced liver damage by HFD or CCl₄, or to control mice, by *i.v.* injection before harvest of livers on day 4. **(A)** Flow cytometry analysis of liver samples for PD-L1 and CD69 expression on CD4⁺ and CD8⁺ T cells are depicted. Representative histograms and bar charts as mean ± SEM % positive cells. **(B)** Liver function was assessed by measuring serum levels of aspartate aminotransferase (AST), alanine transaminase (ALT), albumin (ALB) and total bile acids (TBA), alkaline phosphatase (ALP) and creatinine kinase (CK).

Grey boxes represent the normal range. (Data is presented as mean \pm SEM solute concentration; n=5 per group; unpaired T tests *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001).




Figure 4: Effects of single infusion of *i.v.* reovirus on PD-1, PD-L1 and CD69 expression by T cells in dLN, liver and tumour

1MEA tumour-bearing mice were treated with a single dose of *i.v.* reovirus or PBS (naïve represents untreated mice) prior to organ harvest at 3 or 9 days post-treatment. Single cell suspensions of dLN, liver and tumour were analysed by flow cytometry for **(i)** PD-1, **(ii)** PD-L1 and **(iii)** CD69 expression on **(A)** CD4 and **(B)** CD8 T cells. (Data is presented as mean \pm SEM % positive cells for naïve, PBS (white bars) and reovirus (grey bars); n=5; unpaired T tests *P<0.05, **P<0.01, ***P<0.001).




Figure 5: A single dose of reovirus in combination with PD-L1, rather than PD-1 blockade, delays tumour growth

1MEA tumour-bearing mice were treated with PBS (dashed line / white circles), a single (grey) or repeated (black) doses of *i.v.* reovirus followed by three consecutive days of *i.p.* anti-PD-1 or anti PD-L1 (100 ug) or respective isotype controls. This treatment regime was repeated again 15 days after first treatment began. Survival curves and tumour growth are depicted for combination with PD-1 (A and B, respectively) or PD-L1 (C and D, respectively). Survival curves were compared using Log-rank test. (Tumour growth curves are shown as mean \pm SEM tumour volume for n=7 per group; unpaired T tests *P<0.05, **P<0.01).

ACKNOWLEDGEMENTS

We are grateful to all the patients that participated in these trials. The research is supported by the National Institute for Health Research (NIHR) infrastructure at Leeds. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

STATEMENT OF ETHICS

Ethical approval for both studies was given:

- Reo013 'repeated doses' study; EudraCT number 2007-000258-29; REC reference 08/H1306/73; LTHT R&D approval number CO06/8048
- Reo013 Brain 'single dose' study; EudraCT number 2011-005635-10; REC reference 18/LO/0080; IRAS project ID 235809

All patients gave written informed consent according to good clinical practice guidelines.

CONFLICT OF INTEREST

MC is an employee of Oncolytics Biotech Inc., Calgary from which AS and AAM have received research grants.

FUNDING SOURCES

Funding: AS is the recipient of a Cancer Research UK Clinical Research Fellowship. We are also grateful for support from Yorkshire Cancer Research and in part from Rosetrees Trust (M894) (to SP) and Guts UK (DGO2019_02) (to SP).

AUTHOR CONTRIBUTIONS

Study design: AS, AAM, MC, SP.

Laboratory work and data analysis: KJS, EJW, RJB, FI, AT.

Manuscript preparation: AS, EJW, KJS, RJB

Manuscript final version approval: AS, EJW, KJS, RJB, FI, CR, MC, AAM, AT, SP

DATA AVAILABILITY

All data generated or analysed during this study are included in this article and its supplementary material files. Further enquiries can be directed to the corresponding author.

REFERENCES

- [1] Russell L, Peng KW. The emerging role of oncolytic virus therapy against cancer. *Chin Clin Oncol* 2018;7. <https://doi.org/10.21037/cco.2018.04.04>.
- [2] Steele L, Errington F, Prestwich R, Ilett E, Harrington K, Pandha H, et al. Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF- κ B mediated and supports innate and adaptive anti-tumour immune priming. *Mol Cancer* 2011;10:20. <https://doi.org/10.1186/1476-4598-10-20>.
- [3] Benencia F, Courrèges MC, Conejo-García JR, Mohamed-Hadley A, Zhang L, Buckanovich RJ, et al. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. *Molecular Therapy* 2005;12:789–802. <https://doi.org/10.1016/j.ymthe.2005.03.026>.
- [4] Dolin R, Reichman RC, Fauci AS. Lymphocyte populations in acute viral gastroenteritis. *Infect Immun* 1976;14:422–8. <https://doi.org/10.1128/iai.14.2.422-428.1976>.
- [5] Prestwich RJ, Errington F, Ilett EJ, Morgan RSM, Scott KJ, Kottke T, et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. *Clinical Cancer Research* 2008;14:7358–66. <https://doi.org/10.1158/1078-0432.CCR-08-0831>.
- [6] Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQM, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. *Nature* 2011;477:99–104. <https://doi.org/10.1038/nature10358>.
- [7] Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. *Sci Transl Med* 2018;10. <https://doi.org/10.1126/scitranslmed.aam7577>.
- [8] Adair RA, Roulstone V, Scott KJ, Morgan R, Nuovo GJ, Fuller M, et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. *Sci Transl Med* 2012;4. <https://doi.org/10.1126/scitranslmed.3003578>.
- [9] Gollamudi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, et al. Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors. *Invest New Drugs* 2010;28:641–9. <https://doi.org/10.1007/s10637-009-9279-8>.
- [10] Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, et al. A phase I study of intravenous oncolytic reovirus type 3 dearing in patients with advanced cancer. *Clinical Cancer Research* 2008;14:7127–37. <https://doi.org/10.1158/1078-0432.CCR-08-0524>.
- [11] Russell SJ, Federspiel MJ, Peng KW, Tong C, Dingli D, Morice WG, et al. Remission of disseminated cancer after systemic oncolytic virotherapy. *Mayo Clin Proc* 2014;89:926–33. <https://doi.org/10.1016/j.mayocp.2014.04.003>.
- [12] Warner SG, O’Leary MP, Fong Y. Therapeutic oncolytic viruses. *Curr Opin Oncol* 2017;29:359–65. <https://doi.org/10.1097/CCO.0000000000000388>.
- [13] Bailey K, Kirk A, Naik S, Nace R, Steele MB, Suksanpaisan L, et al. Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters. *PLoS One* 2013;8. <https://doi.org/10.1371/journal.pone.0073759>.
- [14] Miller A, Nace R, Ayala-Breton CC, Steele M, Bailey K, Peng KW, et al. Perfusion pressure is a critical determinant of the intratumoral extravasation of oncolytic viruses. *Molecular Therapy* 2016;24:306–17. <https://doi.org/10.1038/mt.2015.219>.
- [15] Jebar AH, Errington-Mais F, Vile RG, Selby PJ, Melcher AA, Griffin S. Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma.

- Journal of General Virology 2015;96:1533–50.
<https://doi.org/10.1099/vir.0.000098>.
- [16] Lehrman S. Virus treatment questioned after gene therapy death. *Nature* 1999;401:517–8. <https://doi.org/doi:10.1038/43977>.
- [17] Norman KL, Lee PWK. Not all viruses are bad guys: The case for reovirus in cancer therapy. *Drug Discov Today* 2005;10:847–55.
[https://doi.org/10.1016/S1359-6446\(05\)03483-5](https://doi.org/10.1016/S1359-6446(05)03483-5).
- [18] Maier LM, Anderson DE, Severson CA, Baecher-Allan C, Healy B, Liu D V., et al. Soluble IL-2RA Levels in Multiple Sclerosis Subjects and the Effect of Soluble IL-2RA on Immune Responses. *The Journal of Immunology* 2009;182:1541–7. <https://doi.org/10.4049/jimmunol.182.3.1541>.
- [19] Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, et al. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN- γ and IL-12. *Immunity* 2018;49:1148–1161.e7. <https://doi.org/10.1016/j.immuni.2018.09.024>.
- [20] Brandstadter JD, Huang X, Yang Y. NK cell-extrinsic IL-18 signaling is required for efficient NK-cell activation by vaccinia virus. *Eur J Immunol* 2014;44:2659–66. <https://doi.org/10.1002/eji.201344134>.
- [21] Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. *Genes Dev* 2010;24:241–55.
<https://doi.org/10.1101/gad.1874010>.
- [22] Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Review article Natural-killer cells and dendritic cells : “ 1 ’ union fait la force ”. *Blood* 2005;106:2252–8. <https://doi.org/10.1182/blood-2005-03-1154>.Supported.
- [23] Freeman BE, Hammarlund E, Raué HP, Slifka MK. Regulation of innate CD8 + T-cell activation mediated by cytokines. *Proc Natl Acad Sci U S A* 2012;109:9971–6. <https://doi.org/10.1073/pnas.1203543109>.
- [24] Sancho D, Gómez M, Sánchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. *Trends Immunol* 2005;26:136–40.
<https://doi.org/10.1016/j.it.2004.12.006>.
- [25] Zumwalt TJ, Arnold M, Goel A, Boland CR. Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration. *Oncotarget* 2015;6:2981–91.
<https://doi.org/10.18632/oncotarget.3205>.
- [26] Groom JR, Richmond J, Murooka TT, Sorensen EW, Sung JH, Bankert K, et al. *NIH Public Access* 2013;37:1091–103.
<https://doi.org/10.1016/j.immuni.2012.08.016>.CXCR3.
- [27] Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN- γ and CXCR3 ligands. *Cancer Res* 2008;68:8437–45. <https://doi.org/10.1158/0008-5472.CAN-08-1440>.
- [28] Tsou CL, Peters W, Si Y, Slaymaker S, Aslanian AM, Weisberg SP, et al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. *Journal of Clinical Investigation* 2007;117:902–9. <https://doi.org/10.1172/JCI29919>.
- [29] Fountzilias C, Patel S, Mahalingam D. Review: Oncolytic virotherapy, updates and future directions. vol. 8. 2017.
- [30] Rajani K, Parrish C, Kottke T, Thompson J, Zaidi S, Ilett L, et al. Combination therapy with reovirus and Anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. *Molecular Therapy* 2016;24:166–74.
<https://doi.org/10.1038/mt.2015.156>.

- [31] Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. *Sci Transl Med* 2014;6. <https://doi.org/10.1126/scitranslmed.3008095>.
- [32] Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. *Nat Commun* 2017;8:1–12. <https://doi.org/10.1038/ncomms14754>.
- [33] Hardcastle J, Mills L, Malo CS, Jin F, Kurokawa C, Geekiyanage H, et al. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. *Neuro Oncol* 2017;19:493–502. <https://doi.org/10.1093/neuonc/now179>.
- [34] Saha D, Martuza RL, Rabkin SD. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. *Cancer Cell* 2017;32:253-267.e5. <https://doi.org/10.1016/j.ccell.2017.07.006>.
- [35] Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *New England Journal of Medicine* 2020;382:1894–905. <https://doi.org/10.1056/nejmoa1915745>.
- [36] Park HJ, Park JS, Jeong YH, Son J, Ban YH, Lee B-H, et al. PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8 + T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8 + T Cells . *The Journal of Immunology* 2015;194:5801–11. <https://doi.org/10.4049/jimmunol.1401936>.
- [37] Russell SJ. For the Success of Oncolytic Viruses: Single Cycle Cures or Repeat Treatments? (One Cycle Should Be Enough). *Molecular Therapy* 2018;26:1876–80. <https://doi.org/10.1016/j.ymthe.2018.07.003>.
- [38] Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. *Gastroenterology* 2004;127. <https://doi.org/10.1053/j.gastro.2004.09.014>.
- [39] Schuppan D, Afdhal NH. Liver cirrhosis. *Lancet* 2008;371:838–51. [https://doi.org/10.1016/S0140-6736\(08\)60383-9](https://doi.org/10.1016/S0140-6736(08)60383-9).
- [40] Kalas MA, Chavez L, Leon M, Taweeseedt PT, Surani S. Abnormal liver enzymes: A review for clinicians. *World J Hepatol* 2021;13:1688–98. <https://doi.org/10.4254/WJH.V13.I11.1688>.
- [41] Yau T, Park JW, Finn RS, Cheng A-L, Mathurin P, Edeline J, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). *Annals of Oncology* 2019;30:v874–5. <https://doi.org/10.1093/annonc/mdz394.029>.
- [42] Robert C, Schachter J, Long G V., Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. *New England Journal of Medicine* 2015;372:2521–32. <https://doi.org/10.1056/nejmoa1503093>.
- [43] Robert C, Long G V., Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation . *New England Journal of Medicine* 2015;372:320–30. <https://doi.org/10.1056/nejmoa1412082>.
- [44] Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: A histology study of seven cases in comparison with autoimmune hepatitis and

idiosyncratic drug-induced liver injury. *Modern Pathology* 2018;31:965–73.
<https://doi.org/10.1038/s41379-018-0013-y>.